COB Columbia Laboratories Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : COB Columbia Laboratories

COB 14.10

0.0%

Nov 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: cfoe who wrote (631)	1/15/2003 9:23:21 PM
From: wolfdog2	Read Replies (1) of 634

cfoe, I think it's worth holding. Wilkenson, the ceo, seems to be turning this into a real company. Their male testosterone product should get the nod from the FDA by mid year. The stock is, imo, worth more than its current price for the testosterone product alone. Meanwhile COB has a new salesforce marketing C8%, miPhil and Advantage S to obgns. SRA, as you may know also markets C8% to fertility clinics. COB is also testing their delivery system for use in delivery of small molecule peptides. Desmopressin is the first one. In addition, they are now developing Chronodyne with a European partner. They have another product in development as well. Hope this helps.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next